Introduction
============

Myocarditis refers to the clinical and histological manifestations of a broad range of pathological immune processes in the heart.[@B1] It can lead to diverse clinical outcomes ranging from an asymptomatic course to cardiogenic shock, and its natural history is also highly variable ranging from full recovery to the development of dilated cardiomyopathy or sudden cardiac death. Patients with acute myocarditis often present with non-specific symptoms including chest pain, dyspnea, or palpitations, and it usually affects children.[@B2],[@B3] According to clinical guidelines for acute myocarditis, mechanical circulatory support (MCS) is the mainstay of therapy when medications fail or in some patients with fulminant myocarditis.[@B4] In clinical practice, MCS usually involves extracorporeal membrane oxygenation (ECMO) or a ventricular assist device, and several case-series studies have reported both short-term and long-term outcomes in patients with acute myocarditis under MCS.[@B5]-[@B8]

The factors influencing the prognosis of acute myocarditis are also important. Several studies have reported that poor left ventricular systolic function at admission or discharge and in-hospital arrhythmia contribute to poor short-term outcomes.[@B9] In contrast, some studies have reported that these factors do not influence the long-term prognosis of acute myocarditis.[@B10] Several other studies have shown a good prognosis for patients receiving adequate hemodynamic support,[@B9]-[@B11] and even better outcomes for patients with fulminant myocarditis with adequate MCS.[@B6], [@B12]

However, it is currently unclear whether the initial severity of disease or different management strategies including the use and type of MCS affect the long-term outcomes of survivors, especially cardiovascular outcomes. In addition, most studies on clinical outcomes have focused on pediatric patients with myocarditis.[@B6], [@B9], [@B13] According to the reported good outcomes of pediatric patients with acute or even fulminant myocarditis under adequate circulatory support, we hypothesized that the clinical long-term outcomes would be similar in adult patients.

In Taiwan, intra-aortic balloon pump (IABP) and ECMO support are based on the severity of acute myocarditis, and IABP is usually reserved for adults. The aim of this study was to evaluate in-hospital complications and long-term outcomes of patients not receiving and receiving MCS (IABP or ECMO) using a nationwide health insurance database.

Materials and Methods
=====================

Data source and study population
--------------------------------

This nationwide population-based cohort study used data from the National Health Insurance Research Database (NHIRD) released by the Taiwan National Health Research Institute (<http://nhird.nhri.org.tw/en/index.htm>). The NHIRD includes more than 99% of the population in Taiwan, and consists of health care data including gender, birth date, use of medications, management and diagnoses based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM; [www.icd9-data.com/2007](http://www.icd9-data.com/2007)) codes.

We enrolled 5563 patients who were admitted due to acute myocarditis as listed in the NHIRD from January 1, 1997 to December 31, 2011. Patients aged less than 18 years and more than 75 years were excluded, and those who underwent percutaneous coronary interventions during the admission were also excluded. In order to increase the accuracy of the diagnosis of acute myocarditis and the clinical outcomes, only those admitted to an intensive critical unit were enrolled, and we excluded those with cardiovascular comorbidities including ischemic heart disease, peripheral vascular disease, heart failure, a history of stroke, and a history of myocardial infarction. We also excluded the patients with chronic kidney disease or end-stage renal disease requiring long-term dialysis and those with arrhythmic device implantation. We then divided the remaining patients with acute myocarditis into three groups: those who did not receive MCS (non-MCS group), those receiving only IABP support (IABP group), and those receiving ECMO support (ECMO group). The study enrollment flowchart is shown in Figure [1](#F1){ref-type="fig"}.

The enrollees\' original identification numbers are encrypted in the NHIRD to protect privacy. However, the encryption procedure is consistent, so that linking claims belonging to the same enrollee is feasible and can be followed longitudinally.

Acute myocarditis ascertainment, covariates and definition of management
------------------------------------------------------------------------

The diagnosis of acute myocarditis was identified in the NHIRD based on ICD-9-CM code 422. To evaluate the accuracy of this diagnosis, we conducted a validation study in our medical center by reviewing the medical records of hospitalized patients with the ICD-9-CM code of 422. The positive predictive value was 96.5% under the same exclusion criteria in this study. All inpatient files before the index date were used to ascertain comorbidities, which were defined according to ICD-9-CM codes (Table [S1](#SM0){ref-type="supplementary-material"}). All management-related variables during the index admission for acute myocarditis (ICD-9-CM: 422) were obtained from the database. Confirmation examinations included serum virus marker detection, cardiovascular magnetic resonance imaging (CMR) and endomyocardial biopsy (EMB). MCS was defined as IABP or ECMO. Resuscitation programs included defibrillation, intubation with ventilatory support, and cardiac pulmonary resuscitation. Inotropic agents included continuous intravenous infusions with dopamine, norepinephrine and epinephrine, while immunomodulation therapies included intravenous high-dose steroids and intravenous immunoglobulin.

Outcome assessments
-------------------

The clinical outcomes were defined as cardiovascular death, heart failure hospitalization and all-cause mortality in this study. Cardiovascular death was defined according to the criteria of the Standardized Definitions for End Point Events in Cardiovascular Trials drafted by the Food and Drug Administration,[@B14] which included death due to heart failure, myocardial infarction, cardiogenic shock, stroke and other cardiovascular causes such as dysrhythmia, pulmonary embolism, aortic aneurysm rupture or peripheral arterial disease and sudden cardiac death in survivors from acute myocarditis. Heart failure hospitalization was defined according to the primary diagnosis of admission was heart failure (ICD-9-CM: 428). Major cardiovascular diseases and heart failure hospitalization were validated before, and the positive predictive values ranged from 70\~97%[@B15] and around 80%, respectively.[@B16] Secondary outcomes included ventricular tachycardia/ fibrillation (VT/VF), long-term dialysis, stroke, and in-hospital complications, including new onset of high-degree atrioventricular block, VT/VF, acute renal failure, need of hemodialysis, and stroke.

Statistics
----------

The patients\' baseline characteristics, management and resuscitation strategies during the index admission were compared between the study groups using one-way analysis of variance (ANOVA) for continuous variables and the chi-square test for categorical variables. We compared the risk of in-hospital complications among the study groups using multivariate logistic regression analysis with adjustments for age, gender and comorbidities (Table [1](#T1){ref-type="table"}). For the survivors from acute myocarditis, we compared the cardiovascular death and secondary outcomes between study groups using multivariate Cox proportional hazard analysis with adjustments for age, gender, comorbidities (hypertension, diabetes, dyslipidemia and chronic obstructive pulmonary disease), maintenance oral medications (Table [1](#T1){ref-type="table"}) and in-hospital complications including VT/VF, high-degree atrioventricular block and acute renal failure. Due to that death might be a competing risk of HF hospitalization, we performed Fine and Gray\'s sub-distribution hazard model when studying HF hospitalization. Finally, the cumulative incidence of primary outcomes (heart failure hospitalization, cardiovascular death and all-cause mortality) for each study group was calculated using the log-rank test. All data analyses were conducted using SPSS software version 22 (IBM SPSS Inc., Chicago, IL, USA).

Results
=======

In total, 1145 patients with acute myocarditis (mean age 40.2 years, SD 14.8 years) were enrolled in this study, of whom most were young adults (614/53.6%, 18\~39 years). Of these patients, 851 did not need MCS and 294 patients received MCS, including 99 with only IABP and 195 with ECMO support, composited of 60 patients had ECMO support only and 135 patients had both IABP and ECMO support. The baseline characteristics are shown in Table [1](#T1){ref-type="table"}. The distribution of comorbidities was similar among the study groups. There was no significant difference in age between the three study groups.

Management during the admission
-------------------------------

All of the patients enrolled in this study needed ICU care, and a majority needed inotropic agents for shock (dopamine: 48.6%; norepinephrine: 21.2% and epinephrine: 26.0%), especially those who received MCS. With regards to examinations to confirm the diagnosis and detect the origin of acute myocarditis, most patients underwent serum viral marker detection and a few underwent CMR and a biopsy, especially those in the ECMO group (23.1%).

With regards to intensive management and resuscitation strategies, intubation with ventilatory support and resuscitation were required more in the MCS group than in the non-MCS group, and especially in the ECMO group. In addition, the length of ventilator use and cardiac pulmonary resuscitation were also longer in the ECMO group. There were significant differences in all forms of intensive therapy including continuous venovenous hemofiltration and temporary pacemaker placement, and also in the length of ICU and hospital stay (Table [S2](#SM0){ref-type="supplementary-material"}).

In-hospital complications
-------------------------

The incidence of in-hospital complications was higher in the MSC group than in the non-MCS group, and especially in the ECMO group (Table [2](#T2){ref-type="table"}). Acute renal failure was the most common complication, and especially in the ECMO group (25.6%). In addition, VT/VF, acute renal failure, need of hemodialysis, new stroke and in-hospital mortality rates were highest in the ECMO group. Compared to the patients without MCS, those with MCS had higher rates of VT/VF (*vs*. IABP group: p=0.023; *vs*. ECMO group: p\<0.001) and in-hospital mortality (*vs*. IABP group: p=0.002; *vs*. ECMO group: p\<0.001). There was a trend of more renal damage in the IABP group (acute renal failure: p=0.063; need of hemodialysis: p=0.055), and a significantly higher incidence in the ECMO group (acute renal failure: p=\<0.001; need of hemodialysis: p\<0.001). However, there were no differences in high-degree atrioventricular block between the three groups. Comparing the IABP and ECMO groups, the ECMO group had a higher incidence of acute renal failure and in-hospital mortality than the IABP group.

Long-term outcomes in the survivors from acute myocarditis
----------------------------------------------------------

Overall, 91% (780/851) of the patients in the non-MCS group survived to discharge, 80% (80/99) in the IABP group and 61%(119/195) in ECMO group. During the 14-year observation period, the incidence of heart failure hospitalization was around 6\~8% in the survivors, and no significant difference was noted between the three groups (p=0.742) (Table [3](#T3){ref-type="table"} and Figure [S1](#SM0){ref-type="supplementary-material"}). The incidence of cardiovascular death ranged from 10% to 22%, and the incidence in who received ECMO (21.8%) was higher than the rate in those who had no MCS or those who had IABP. The difference among the three groups was significant (hazard ratio \[HR\]: 3.88; 95% confidence interval \[CI\]: 2.93-5.12 for the ECMO *vs*. non-MCS group; HR: 2.74; 95% CI: 1.70-4.40 for ECMO *vs*. IABP group) (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}A). When analyzing cardiovascular death in different periods, the difference appeared within 3 months (p\<0.001) but it disappeared after 3 months (p=0.458) (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}B). In addition, cardiovascular death majorly occurred within 3 months after discharge. In terms of all-cause mortality, the trend of differences between groups was similar as it in cardiovascular death (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Of the secondary outcomes, there were low incidence rates of long-term dialysis (0% to 1.3%), VT/VF (0% to 1.3%) and new stroke (0% to 3.6%). Furthermore, there were no significant differences in these secondary outcomes between the three groups (Table [3](#T3){ref-type="table"}).

Subgroup analysis between the patients without MCS but receiving inotropic agents and those with MCS
----------------------------------------------------------------------------------------------------

In total, 328 patients inotropic agents in the non-MCS group. There were no significant differences in baseline characteristics, examinations, medications, intensive managements and resuscitation strategies between the patients without MCS but receiving inotropic agents and those with MCS (Table [S3](#SM0){ref-type="supplementary-material"} and Table [S4](#SM0){ref-type="supplementary-material"}) as compared to the original groups (non-MCS, IABP and ECMO groups). With regards to in-hospital complications, there were still significant differences in VT/VF, acute renal failure and all-cause mortality (Table [S5](#SM0){ref-type="supplementary-material"}). With regards to long-term outcomes, the highest incidence of death was noted in the ECMO group, but no significant differences in heart failure hospitalization and other secondary outcomes between groups (Table [S6](#SM0){ref-type="supplementary-material"}, Figure [S2](#SM0){ref-type="supplementary-material"}).

Discussion
==========

From this national cohort retrospective study, we though more severity still leads more risk of cardiovascular death and all-cause mortality in survivors from acute myocarditis. Although our result was different from it presented in pediatric population before, the severity of disease affect mortality within 3 months but did not thereafter.

In literature, the majority of patients with acute myocarditis are young males.[@B17], [@B18] and this is consistent with our study, in which 59.3% of the patients were young males. According to the management of myocarditis, including medication or MCS, depends on the severity of the disease,[@B19] and mechanical cardiopulmonary life support should be immediately used when circulatory insufficiency cannot be reversed with conventional medical treatment. Therefore, it is reasonable to classify the severity of the study population according to the usage of inotropic agents and the need of MCS. In this study, the prevalence of in-hospital complications related to acute myocarditis, such as VT/VF and acute renal failure, intensive management and resuscitation strategies were higher in the patients who received MCS, especially in those who need ECMO support. Such clinical presentations might further confirm the different degree of severity between groups divided by MCS.

There were several methods to identify acute myocarditis whose included EMB and CMR but they usually were limited in clinical practice. The use of EMB is limited due to a high complication rate, sampling error, sampling time, pathological interpretation and the need for specialist interpretation.[@B3], [@B20], [@B21] In addition, the correlation between management strategies and biopsy results has been reported to be poor.[@B8] In this study, EMB was performed in 7.1% of the patients. In terms of CMR, it is increasingly used as an alternative diagnostic tool due to its non-invasive nature and because it can reveal the whole cardiac structure.[@B22] However, it is also limited by a long examination time and the clinical severity of acute myocarditis. CMR was performed in 4.5% of our patients, which may be because all of our patients required ICU.[@B19] In addition, although the major etiology of acute myocarditis is viral infection,[@B23] Kindermann I *et al.* concluded that neither Dallas\'s criteria nor the detection of a viral genome was a predictor of outcome[@B24] and a study about biopsy-proven viral myocarditis also presented types of virus cannot predict long-term outcomes.[@B25] Looking back our result that the primary outcomes from this population without an autoimmune disease were not affected by CMR, EMB or viral infection (Table [S7](#SM0){ref-type="supplementary-material"}).

The outcomes of acute myocarditis reported in the literature are recovery in nearly 50% of cases, more than 60% survival to discharge [@B5], [@B26] and 12-25% mortality or progression to end-stage dilated cardiomyopathy.[@B12], [@B25] our results presented the similar results as it presented. The original concept, based mainly on pediatric population, is that if patients with this condition survive the critical few days for recovery of myocardial function, getting the required pharmacological and mechanical support, their long-term prognosis may be good.[@B3] Some studies have reported that adult fulminant myocarditis has an excellent prognosis if patients receive adequate hemodynamic support, even though patients with fulminant myocarditis have more severe heart condition than those with acute myocarditis.[@B7], [@B12] In addition, several studies have evaluated which factors influence the prognosis of patients with acute myocarditis. Although a study reported that initial left ventricular systolic function was a marker for prognosis regardless of the clinical pattern of disease onset, [@B18] but another study did not.[@B25] In terms of initial clinical status, Stefan Grün *et al.* reported initial heart function class was a good predictor of incomplete recovery under multivariable regression analysis.[@B25] As similar result phenomenon in our study, we presented the initial severity would affect the clinical outcomes after discharge, although we cannot take the ventricular function into analysis. The main strength of this nationwide case-control cohort study on acute myocarditis is the large number of patients (over 1000). In further subgroup analysis in different period after discharge, there were two interesting phenomenon. First, the incidences of cardiovascular death and all-cause mortality were higher when the severity of disease was more severe within 3 months after discharge but the trend disappeared thereafter. Second, the majority of death occurred within 3 months after discharge, but the event of heart failure hospitalization did not. In addition, cardiovascular death is the major component of all-cause mortality. Accordingly, we though the severity of disease would affect the short-term but not long-term mortality and major cause of cardiovascular would not be heart failure.

Study limitations
-----------------

There are several limitations to this study. First, the accuracy of the diagnosis of acute myocarditis could not be verified. According to Dallas\`s criteria,[@B27] EMB is the gold standard method to make a diagnosis. However, its performance rate has been reported to be relatively low in clinical practice due to several limitations.[@B3], [@B20], [@B21] In addition, patients with clinical presentations plus elevated troponin I/troponin T levels or abnormal electrocardiograms/echocardiograms[@B19] can be classified in the clinical classification of \'probable acute myocarditis\'.[@B1] Therefore, in order to increase the accuracy of diagnosis, we recorded all possible management strategies of the patients with acute myocarditis, and selected those who needed intensive care. Furthermore, we excluded patients who had undergone coronary interventions and those with several comorbidities, which may affect the diagnosis. Thus, the diagnosis of acute myocarditis can be presumed to be highly accurate and the positive predictive value was around 96% in our validation.

Second, some factors that may affect long-term outcomes could not be obtained from the NHIRD, including biopsy results, the types of infecting virus, imaging results and left ventricular function. However, the aim of this study was to evaluate the correlation between in-hospital complications and long-term outcomes and the use of MCS. Thus, laboratory data or imaging results may have little influence on the conclusions. In addition, some previous studies have reported controversial results when evaluating examinations, including ventricular function and types of virus, for acute myocarditis.[@B21], [@B23],[@B25] Third, the severity of disease could not be assessed by ICD-9-CM code, and clinical hemodynamic data were not available to confirm the severity. Finally, the data used in this study came from the National Health Insurance system of Taiwan, which includes a large number of patients, and the complete follow-up should counterbalance the inherent study weaknesses, and thereby ameliorate some of the limitations.

Conclusion
==========

The incidence of heart failure hospitalization was low in long-term follow-up, and it was not significantly correlated with the type of MCS, while the risks of cardiovascular death and all-cause mortality were the highest in patients needed ECMO. Accordingly, cardiovascular death is the leading cause of all-cause mortality and the risk of cardiovascular mortality in short-term period was closely associated with the severity of acute myocarditis but not long-term period. Therefore, be attention to the cardiovascular death within 3 months after index admission and it is an important issue about preventing sudden cardiac death, in acute myocarditis patient needed MCS.
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![Kaplan-Meier estimates of the cumulative incidence of cardiovascular death between three groups: non-MCS group, IABP group and ECMO group. (**A**) The cumulative incidence of cardiovascular death after index admission. (**B**) The cumulative incidence of cardiovascular death within 3 months and after 3 months after index admission. ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; MCS: mechanical circulatory support.](ijmsv14p1241g002){#F2}

![Kaplan-Meier estimates of the cumulative incidence of all-cause mortality between three groups: non-MCS group, IABP group and ECMO group. (A) The cumulative incidence of all-cause mortality after index admission. (B) The cumulative incidence of all-cause mortality within 3 months and after 3 months after index admission. ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; MCS: mechanical circulatory support.](ijmsv14p1241g003){#F3}

###### 

Baseline characteristics and management during admission

  Variable                                           Total        Non-MCS      IABP        ECMO         *P*
  -------------------------------------------------- ------------ ------------ ----------- ------------ ---------
  Number of patients                                 1,145        851          99          195          \-
  Male gender                                        677 (59.3)   530 (62.5)   59 (59.6)   88 (45.1)    \<0.001
  Age (years)                                        40.2±14.8    39.6±15.0    44.8±15.6   40.5±13.1    0.004
  Age group (years)                                                                                     0.003
  18\~39                                             614 (53.6)   470 (55.2)   45 (45.5)   99 (50.8)    
  40\~59                                             383 (33.4)   276 (32.4)   30 (30.3)   77 (39.5)    
  ≧60                                                148 (12.9)   105 (12.3)   24 (24.2)   19 (9.7)     
  Underlying disease                                                                                    
  Hypertension                                       112 (9.8)    88 (10.3)    12 (12.1)   12 (6.2)     0.148
  Diabetes                                           91 (7.9)     68 (8.0)     13 (13.1)   10 (5.1)     0.056
  Dyslipidemia                                       35 (3.1)     29 (3.4)     5 (5.1)     1 (0.5)      0.051
  COPD                                               40 (3.5)     26 (3.1)     6 (6.1)     8 (4.1)      0.268
  **Examination during the admission**                                                                  
  Heart MRI                                          51 (4.5)     40 (4.7)     4 (4.0)     7 (3.6)      0.777
  Cardiac biopsy                                     81 (7.1)     28 (3.3)     8 (8.1)     45 (23.1)    \<0.001
  Serum virus detection                              747 (65.2)   516 (60.6)   65 (65.7)   166 (85.1)   \<0.001
  Coronary angiography                               427 (43.6)   297 (38.1)   60 (75.0)   70 (58.8)    \<0.001
  **Intravenous medications during the admission**                                                      
  Dobutamine                                         361 (31.5)   199 (23.4)   57 (57.6)   105 (53.8)   \<0.001
  Milrinone                                          34 (3.0)     2 (0.2)      3 (3.0)     29 (14.9)    \<0.001
  Dopamine                                           557 (48.6)   312 (36.7)   73 (73.7)   172 (88.2)   \<0.001
  Norepinephrine                                     243 (21.2)   85 (10.0)    39 (39.4)   119 (61.0)   \<0.001
  Epinephrine                                        298 (26.0)   107 (12.6)   37 (37.4)   154 (79.0)   \<0.001
  High dose of steroid                               51 (4.5)     20 (2.4)     5 (5.1)     26 (13.3)    \<0.001
  IVIG                                               27 (2.4)     4 (0.5)      2 (2.0)     21 (10.8)    \<0.001
  Heparin                                            545 (47.6)   291 (34.2)   73 (73.7)   181 (92.8)   \<0.001
  Enoxaparin                                         121 (10.6)   97 (11.4)    12 (12.1)   12 (6.2)     0.087
  **Oral medication for maintain usage**                                                                
  ACEi/ARB                                           503 (43.9)   386 (45.4)   48 (48.5)   69 (35.4)    0.026
  Beta blocker                                       375 (32.8)   283 (33.3)   39 (39.4)   53 (27.2)    0.089
  Digoxin                                            206 (18.0)   145 (17.0)   24 (24.2)   37 (19.0)    0.195
  K sparing diuretics                                152 (13.3)   97 (11.4)    28 (28.3)   27 (1.8)     \<0.001
  Statin                                             61 (5.3)     47 (5.5)     8 (8.1)     6 (3.1)      0.173
  Antiplatelets                                      514 (44.9)   407 (47.8)   50 (50.5)   57 (29.2)    \<0.001

ACEi/ARB: angiotensin converting enzyme inhibitors/angiotensin receptor blocker; ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; IVIG: intravenous immunoglobulin; MCS: mechanical circulation support; MRI: magnetic resonance imaging; COPD: chronic obstructive pulmonary disease.

###### 

In-hospital complications

  Variable               Number of events (%)               Adjusted odds ratio and 95% CI‡                                                                                        
  ---------------------- ---------------------- ----------- --------------------------------- -- ------------------ ------- -- ------------------- --------- -- ------------------ -------
  VT/VF                  50 (5.9)               12 (12.1)   34 (17.4)                            2.19 (1.12-4.32)   0.023      2.98 (1.85-4.81)    \<0.001      1.36 (0.66-2.80)   0.405
  High degree AV block   61 (7.2)               8 (8.1)     11 (5.6)                             1.14 (0.53-2.48)   0.738      0.80 (0.41-1.57)    0.523        0.70 (0.27-1.83)   0.471
  Acute renal failure    61 (7.2)               13 (13.1)   50 (25.6)                            1.86 (0.97-3.56)   0.063      4.71 (3.08-7.23)    \<0.001      2.54 (1.28-5.03)   0.007
  Need of hemodialysis   20 (2.4)               6 (6.1)     24 (12.3)                            2.52 (0.98-6.50)   0.055      5.77 (3.07-10.83)   \<0.001      2.29 (0.88-5.92)   0.088
  New onset of stroke    19 (2.2)               1 (1.0)     13 (6.7)                             0.42 (0.06-3.20)   0.403      2.92 (1.40-6.09)    0.004        6.95 (0.89-54.5)   0.065
  Pneumonia              114 (13.4)             12 (12.1)   24 (12.3)                            0.83 (0.44-1.59)   0.581      0.87 (0.54-1.41)    0.576        1.05 (0.49-2.21)   0.907
  Sepsis                 115 (13.5)             24 (24.2)   36 (18.5)                            1.87 (1.12-3.11)   0.017      1.28 (0.84-1.95)    0.252        0.69 (0.38-1.25)   0.218
  In-hospital death      71 (8.3)               19 (19.2)   76 (39.0)                            2.47 (1.40-4.36)   0.002      6.86 (4.66-10.12)   \<0.001      2.78 (1.53-5.05)   0.001

Abbreviation: AV block: atrioventricular block; VT/VF: ventricular tachycardia/ventricular fibrillation

OR: odds ratio; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; MCS: mechanical circulation support

‡ Adjusted for age, gender, and the baseline characteristics listed in Table [1](#T1){ref-type="table"}

###### 

Long-term outcomes of the survivors from acute myocarditis

  Variable                               Number of events (%)               Adjusted hazard ratio and 95% CI‡                                                                                           
  -------------------------------------- ---------------------- ----------- ----------------------------------- -- ------------------- ------- -- ------------------- --------- -- -------------------- ---------
  **Primary outcomes**                                                                                                                                                                                  
  HF hospitalization\*                   65 (8.3)               5 (6.3)     10 (8.4)                               0.58 (0.23, 1.46)   0.248      0.69 (0.34, 1.40)   0.303        1.18 (0.39, 3.56)    0.767
  HF hospitalization within 3 months\*   20 (2.6)               3 (3.8)     2 (1.7)                                1.56 (0.48, 5.06)   0.462      0.44 (0.09, 2.15)   0.311        0.28 (0.05, 1.70)    0.168
  HF hospitalization after 3 months\*    45 (5.8)               2 (2.5)     8 (6.7)                                0.27 (0.06, 1.20)   0.085      1.18 (0.49, 2.82)   0.716        4.43 (0.85, 23.19)   0.078
  CV death                               101 (12.9)             8 (10.0)    26 (21.8)                              1.42 (0.90, 2.24)   0.136      3.88 (2.93, 5.12)   \<0.001      2.74 (1.70, 4.40)    \<0.001
  CV death within 3 months               32 (4.1)               4 (5.0)     19 (16.0)                              2.39 (1.41, 4.05)   0.001      5.28 (3.79, 7.36)   \<0.001      2.21 (1.31, 3.74)    0.003
  CV death after 3 months                69 (8.8)               4 (5.0)     7 (5.9)                                0.52 (0.19, 1.45)   0.213      1.04 (0.50, 2.14)   0.924        1.98 (0.60, 6.55)    0.262
  All-cause mortality                    197 (25.3)             12 (15.0)   32 (26.9)                              0.53 (0.30, 0.97)   0.038      1.42 (0.96, 2.10)   0.084        2.65 (1.35, 5.20)    0.005
  Mortality within 3 months              86 (11.0)              4 (5.0)     22 (18.5)                              0.50 (0.18, 1.38)   0.179      2.01 (1.22, 3.30)   0.006        4.03 (1.37, 11.84)   0.011
  Mortality after 3 months               111 (14.2)             8 (10.0)    10 (8.4)                               0.53 (0.26, 1.11)   0.090      0.87 (0.44, 1.73)   0.690        1.64 (0.63, 4.26)    0.310
  **Secondary outcomes**                                                                                                                                                                                
  Long-term dialysis                     10 (1.3)               0 (0.0)     0 (0.0)                                NA                  NA         NA                  NA           NA                   NA
  VT/VF                                  10 (1.3)               0 (0.0)     1 (0.8)                                NA                  NA         0.24 (0.02-2.28)    0.214        NA                   NA
  Stroke                                 28 (3.6)               0 (0.0)     1 (0.8)                                NA                  NA         0.34 (0.04-2.66)    0.303        NA                   NA

Abbreviation: CV death: cardiovascular death; HF: heart failure, VT/VF: ventricular tachycardia/ventricular fibrillation

HR: hazard ratio; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; MCS: mechanical circulation support;

[^1]: \* Contributed equally as first authors

[^2]: Competing Interests: The authors have declared that no competing interest exists.
